Need to keep on prime of the science and politics driving biotech as we speak? Join to get our biotech e-newsletter in your inbox.
The Trump administration is utilizing newly introduced 100% tariffs as leverage to push each massive and small drugmakers into confidential pricing and manufacturing agreements.
Additionally, the burgeoning peptide craze is highlighting a belief hole in medication, by which sufferers more and more favor unproven therapies over well-established medicine.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
